Blood pressure and Lipids
The IFG group had a statistically higher systolic and diastolic blood pressure, fasting triglycerides and LDL at baseline compared to the group with normal fasting glucose.
The patients with IFG had higher median, with a 95% confidence interval, systolic blood pressure at baseline 127.2±1.1mmHg compared to the normal fasting glucose group patients 123.8±1.1mmHg, p<0.001). There was significant reduction of systolic blood pressure at month 3 for both groups compared to baseline (IFG patients 121.3±1mmHg p<0.001and normal fasting glucose patients 118.9± 1mmHg p<0.001).
The patients with IFG also had higher median, with a 95% confidence interval, diastolic blood pressure at baseline (IFG patients 81.9±2.6 mmHg vs the normal fasting glucose group 79.5 ±2.4mmHg, p<0.001). There was a significant reduction of diastolic blood pressure at month 6 for both groups compared to baseline (IFG patients 77.3±mmHg p<0.001and normal fasting glucose patients 75.5±2mmHg p<0.001).
The baseline total cholesterol was comparable in all patients. The triglyceride level for IFG patients was significantly decreased at month 3 by 45.2 ±64.2 mg/dl (p<0.0001). The high-density lipoprotein cholesterol level for patients in both groups was significantly increased in association with weight loss, but without any significant difference between groups. There was a significant decrease of low-density lipoprotein at month 3 by 10.9 ±29.45.18 mg/dl (p<0.0001) for the IFG group and by 12.8 ±31.6 (p<0.0001) in the group with normal fasting blood glucose.